0 0

Join us for an engaging interview with Carrie Mason, Head od the PAT Centre of Excellence at Lonza, where she discusses the latest trends shaping the analytics industry. Topics include the evolution of PAT tools, the importance of sustainability in analytics practices, and the transformative role of AI.

4 0

It was great to chat with Any Fenny, CCO at SK Pharmteco. We’ll talk about the new directions the company is heading, recent expansions, and some of the exciting investments they’ve been making. It’s a great chance to hear directly from Andy about what’s next for SK Pharmteco and how they’re evolving in the industry.

1 0

Peter Bains, MD & CEO of Syngene International, joins 24/7 Biopharma to discuss the company’s global CRDMO model, growing clinical trial capabilities in India, and its U.S. expansion through the Bayview facility in Baltimore. He highlights Syngene’s end-to-end R&D support for both small and large molecules, its 6,000-strong scientific team, and its work with 75% of the top 25 pharma companies. Bains also highlights SynVent, Syngene’s integrated discovery engine, as a key driver of early-stage biotech partnerships and future growth.

1 0

Really looking forward to sharing a chat with Chris Worrall from Nanoform. We talk about the exciting world of nanomedicine, how they’re putting patients at the center of their work, and catch up on their latest news. Watch the full interview here — you won’t want to miss it!

1 0

In this interview, Nigel Stapleton from Mabion shares the exciting news about their new “Unlocking the Future of Therapeutics” competition. It’s a great opportunity for innovators working on biologics, especially in cancer treatment. Mabion is offering €500,000 in development services to help develop and scale up the most promising projects — whether that’s a brand new therapy or a biosimilar that can make life-saving treatments more accessible. Nigel also talks about how they’re working with top cancer researchers to pick out the best candidates, all part of their mission to push forward the future of cancer care.

1 0

We sat down with Pietro Allegrini, R&D Director at Indena, to discuss their recent strategic investments in the CDMO space. Pietro shares insights into Indena’s advancements in highly potent compounds, cutting-edge technologies, and their latest developments in ADC activities. He also talks about the expanding capacities and the company's commitment to innovation in the pharmaceutical industry. Stay tuned for an in-depth look at how Indena is shaping the future of biopharmaceutical development.

0 0

BIO International Convention Boston 2025 - This interview features Himanshu Gadgil, PhD,
CEO from Enzene, discussing their new biologics manufacturing facility in New Jersey, industry trends, supply chain strategies, and challenges unique to biologics. The conversation also highlights Enzene’s key achievements and their approach to advancing biopharma innovation.

2 0